DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Midostaurin

First Posted Date: 2022-08-04

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT05488613

Locations: 🇫🇮
Novartis Investigative Site, Helsinki, Finland

Study Conducted Among Patients With CML

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Other: Tyrosine Kinase Inhibitors (TKIs)

First Posted Date: 2022-07-27

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3234

Registration Number: NCT05476562

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1

Recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: NIO752
Drug: Matching placebo

First Posted Date: 2022-07-21

Last Posted Date: 2025-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT05469360

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Esophageal Squamous Cell Carcinoma

Interventions: Biological: QEQ278

First Posted Date: 2022-07-18

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05462873

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States

and more 1 locations

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

Phase 2

Terminated

Conditions: Osteoarthritis, Knee

Interventions: Drug: QUC398
Drug: Placebo

First Posted Date: 2022-07-18

Last Posted Date: 2025-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 101

Registration Number: NCT05462990

Locations: 🇺🇸
Clinical Research of West Florida Inc, Tampa, Florida, United States
🇺🇸
Boston Univ School Of Medicine, Boston, Massachusetts, United States
🇺🇸
West Clinical Research, Morehead City, North Carolina, United States

and more 1 locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Phase 3

Active, not recruiting

Conditions: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Asciminib

First Posted Date: 2022-07-13

Last Posted Date: 2025-04-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 568

Registration Number: NCT05456191

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Boulder, Colorado, United States
🇺🇸
Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸
Regions Hospital, Saint Paul, Minnesota, United States

and more 7 locations

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Phase 2

Completed

Conditions: Treatment-Resistant Depression

Interventions: Drug: MIJ821 Subcutaneous Injection 1 mg
Drug: MIJ821 Subcutaneous Injection 4 mg
Drug: Placebo Subcutaneous Injection
Drug: MIJ821 Subcutaneous Injection 10 mg

First Posted Date: 2022-07-12

Last Posted Date: 2025-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05454410

Locations: 🇺🇸
25Uni of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Research Centers of America LLC, Oakland Park, Florida, United States
🇺🇸
Interventional Psychiatry Tampa Bay, Tampa, Florida, United States

and more 1 locations

Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

Completed

Conditions: Heart Failure

Interventions: Drug: Sacubitril/Valsartan

First Posted Date: 2022-07-08

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 924

Registration Number: NCT05448872

Locations: 🇮🇹
Novartis Investigative Site, Trieste, Italy

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Allogeneic Stem Cell Transplantation

Interventions: Drug: Siremadlin

First Posted Date: 2022-07-07

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT05447663

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Phase 2

Active, not recruiting

Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Interventions: Drug: JDQ443

First Posted Date: 2022-07-06

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT05445843

Locations: 🇺🇸
The Brown University Oncology Group, Providence, Rhode Island, United States
🇬🇧
Novartis Investigative Site, Torquay, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy